TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media
Download Report PDF Instantly
Report overview
MARKET INSIGHTS
Global HILIC Columns market size was valued at USD 150 million in 2025. The market is projected to grow from USD 155 million in 2026 to USD 260 million by 2034, exhibiting a CAGR of 6.3% during the forecast period.
HILIC Columns refer to chromatographic columns designed for Hydrophilic Interaction Liquid Chromatography (HILIC). This technique is widely used in analytical chemistry for separating and analyzing polar and hydrophilic compounds. The stationary phase of these columns is polar, while the mobile phase typically includes a high percentage of organic solvent, such as acetonitrile, mixed with a small amount of water or buffer. Key manufacturers such as Thermo Fisher Scientific, Agilent, Merck, Restek and Phenomenex dominate the market, together accounting for roughly 55% of global revenue in 2025.
The global HILIC Columns market was valued at US$140 million in 2025 and is projected to reach US$189 million by 2032, at a CAGR of 4.4% during the forecast period. HILIC (Hydrophilic Interaction Liquid Chromatography) columns are designed with a polar stationary phase that enables efficient separation of highly polar and hydrophilic analytes. The mobile phase typically contains a high proportion of an organic solvent such as acetonitrile, supplemented with a minor aqueous buffer, creating the unique retention mechanism essential for pharmaceutical, biological, chemical, and food‑and‑beverage analyses. The United States market size is estimated at several hundred million dollars in 2025, while China is expected to become a rapidly expanding hub, reflecting strong demand from life‑science research and biopharma manufacturing. The silica‑based segment, historically dominant because of its robustness and reproducibility, is forecast to retain the largest share and is expected to reach a multi‑million‑dollar valuation by 2032, driven by a steady compound annual growth rate.
Increased Use of Next‑generation Sequencing to Drive Use of HILIC Columns
Next‑generation sequencing (NGS) platforms generate massive volumes of polar nucleic‑acid fragments, metabolites, and small‑molecule intermediates that require high‑resolution separation prior to detection. HILIC columns, with their superior retention of hydrophilic species, have become indispensable in sample‑preparation workflows for library construction, quality‑control assays, and quantitative biomarker profiling. The rapid adoption of NGS in clinical genomics—supported by decreasing sequencing costs that have fallen below US$600 per whole‑genome run—has amplified the demand for column technologies that can resolve complex mixtures of nucleotides, nucleosides, and phosphorylated compounds. Moreover, recent instrument upgrades that augment solvent‑mixing precision have heightened the reproducibility of HILIC separations, prompting leading instrument manufacturers to bundle dedicated HILIC column packs with their next‑generation sequencers. This convergence of technology and market need is propelling a sustained increase in column shipments, particularly in high‑throughput core facilities across North America and Europe.
Growing Demand for Personalized Medicine to Boost Market Growth
Personalized medicine relies on the precise quantitation of therapeutic metabolites, endogenous biomarkers, and drug‑related impurities—all of which are often highly polar. HILIC chromatography provides the necessary selectivity to monitor these analytes at sub‑nanomolar concentrations, enabling clinicians to tailor dosing regimens based on individual pharmacokinetic profiles. The global personalized‑medicine market, surpassing US$120 billion in 2024, has driven laboratories to upgrade their analytical suites with HILIC columns that can cope with the stringent regulatory requirements for bio‑equivalence and therapeutic‑drug‑monitoring studies. In oncology, for example, the detection of mutated nucleic‑acid fragments in circulating tumor DNA (ctDNA) often requires HILIC‑based enrichment steps to achieve the sensitivity required for early‑stage disease detection. The cumulative effect of expanding therapeutic areas—oncology, rare‑disease genetics, and autoimmune disorders—has therefore translated into a robust, recurring demand for HILIC columns across both research and clinical settings.
Regulatory agencies worldwide have introduced guidance documents that emphasize the need for orthogonal separation techniques to confirm product purity. In response, manufacturers have accelerated the development of HILIC columns with enhanced batch‑to‑batch consistency, incorporating proprietary silica chemistries that reduce column‑to‑column variability to less than 2 %. This regulatory push not only reinforces market confidence but also creates a virtuous cycle where compliance‑driven procurement fuels further investment in column innovation.
Strategic Mergers, Acquisitions, and Geographic Expansion
Over the past three years, the HILIC column market has witnessed a wave of consolidation as major analytical‑instrument firms acquire niche column manufacturers to broaden their product portfolios. Notable transactions include a multi‑billion‑dollar acquisition of a leading HILIC specialist by a global life‑science conglomerate, and strategic joint ventures between European column producers and Asian distribution partners aimed at localizing production in China and India. These moves have shortened lead times, reduced freight costs, and allowed customers in emerging markets to access the latest column technologies at competitive prices. The resulting economies of scale have also enabled price‑optimization programs that make high‑performance HILIC columns more affordable for small‑ and medium‑sized laboratories, further widening the addressable market.
MARKET CHALLENGES
High Costs of Advanced HILIC Columns Tends to Challenge Market Growth
Although HILIC columns deliver unmatched selectivity for polar analytes, the sophisticated surface chemistries and stringent quality‑control processes required to achieve low‑level carryover and high reproducibility drive up manufacturing expenses. In price‑sensitive segments such as academic research and early‑stage biotech startups, the cost premium—often exceeding 30 % relative to conventional reversed‑phase columns—can limit adoption, especially when budgets are constrained by grant‑funding cycles. Additionally, the need for specialized column‑conditioning protocols and rigorous validation for regulatory submissions adds hidden operational costs, discouraging some laboratories from transitioning away from legacy technologies.
Other Challenges
Regulatory Hurdles
Stringent regulations governing the validation of analytical methods for pharmaceutical and clinical applications can impede the rapid rollout of new HILIC products. Companies must invest significant resources to generate method‑validation dossiers, conduct extensive robustness studies, and secure approvals from agencies such as the FDA and EMA. The time‑intensive nature of these processes can delay market entry and discourage smaller manufacturers from developing innovative column chemistries.
Ethical Concerns
While not directly linked to column technology, the broader context of hydrophilic interaction chromatography in the analysis of genetic material raises ethical considerations related to data privacy and the potential misuse of highly sensitive biomarker information. Companies must therefore implement strict data‑handling policies and ensure compliance with emerging bio‑ethics frameworks, adding another layer of complexity to product development and commercialization.
Technical Complications and Shortage of Skilled Professionals to Deter Market Growth
HILIC chromatography demands meticulous control of mobile‑phase composition, temperature, and pH to maintain reproducible retention times. Small deviations can lead to significant peak‑shape distortions, especially when separating highly polar metabolites. This technical sensitivity creates a barrier for laboratories lacking experienced chromatographers or advanced automation platforms. Moreover, the industry faces a talent gap; a recent workforce survey reported that over 40 % of analytical‑chemistry positions remain unfilled due to a shortage of specialists proficient in HILIC method development. The combination of complex method‑setup requirements and limited human expertise slows adoption, particularly in regions where analytical talent pipelines are still maturing.
The scaling of HILIC column production also presents challenges. Maintaining consistent silica‑particle size distribution and surface functionalization across large batches requires sophisticated manufacturing equipment and stringent clean‑room conditions. Any variation can compromise column performance, leading to higher rejection rates and increased production costs. Companies that fail to achieve tight process control risk losing market share to competitors that have invested in next‑generation manufacturing lines capable of delivering ultra‑low‑variability columns at scale.
Finally, the integration of HILIC columns into existing liquid‑chromatography workflows often necessitates additional hardware—such as high‑precision gradient mixers and temperature‑controlled column compartments—that many laboratories are reluctant to procure. The capital outlay needed to retrofit legacy systems can be prohibitive, especially for small research institutions, thereby restraining overall market penetration.
Surge in Number of Strategic Initiatives by Key Players to Provide Profitable Opportunities for Future Growth
Investment in molecular‑diagnostics platforms that rely on polar‑compound separation is accelerating, creating a fertile environment for HILIC column suppliers. Major players are forging partnerships with diagnostic‑device manufacturers to co‑develop cartridge‑based HILIC solutions that enable point‑of‑care testing for metabolic disorders and infectious‑disease biomarkers. These collaborations shorten time‑to‑market and open new revenue streams beyond traditional laboratory‑scale sales. In Asia, several biotech clusters are establishing dedicated HILIC‑column production lines to serve regional pharmaceutical companies seeking rapid bio‑analysis capabilities, thereby expanding the geographic footprint of the market.
Innovation pipelines are also delivering next‑generation HILIC chemistries, such as mixed‑mode phases that combine zwitterionic and polymeric functionalities, offering improved retention for a broader range of analytes. Early adopters report up to a 25 % reduction in analysis time while maintaining comparable limits of detection. Such performance gains make a compelling value proposition for contract‑research organisations (CROs) aiming to increase throughput without compromising data quality, presenting a sizeable opportunity for manufacturers that can commercialise these advanced phases.
Regulatory bodies are increasingly endorsing orthogonal analytical approaches, including HILIC, as part of the quality‑by‑design (QbD) framework for pharmaceutical development. This endorsement encourages drug‑developer firms to incorporate HILIC methods early in the drug‑discovery lifecycle, driving long‑term demand for columns that meet stringent validation criteria. Companies that align their product roadmaps with evolving QbD guidelines and provide comprehensive validation packages are thus well‑positioned to capture a growing share of the market.
Silica‑Based Segment Leads the Market Due to Superior Stability and High Load‑Capacity
The market is segmented based on type into:
Silica‑Based
Polymer‑Based
Zwitterionic
Mixed‑Phase
Others
Molecular Diagnostics Segment Leads Due to High Adoption in Disease Detection and Precision Medicine
The market is segmented based on application into:
Molecular diagnostics
Pharmaceutical development
Academic and research institutions
Food & beverage analysis
Environmental testing
Others
Companies Strive to Strengthen their Product Portfolio to Sustain Competition
The global HILIC Columns market was valued at US$140 million in 2025 and is projected to reach US$189 million by 2032, growing at a CAGR of 4.4 %. This semi‑consolidated market comprises large, medium and niche players that serve analytical chemistry, pharmaceutical, and food‑and‑beverage segments. Thermo Fisher Scientific Inc. remains a clear market leader, benefiting from an extensive product portfolio that includes silica‑based and zwitterionic columns, and a robust distribution network across North America, Europe and Asia‑Pacific.
Agilent Technologies Inc. and Merck KGaA have secured significant market share through continuous innovation in polymer‑based and mixed‑mode HILIC technology. Their recent launches—such as Agilent’s “ZORBAX HILIC Plus” series and Merck’s “SeQuant ZIC‑HILIC” columns—address growing demand for higher resolution separations in biopharmaceutical analysis.
In addition, Waters Corporation, Shimadzu and Phenomenex are expanding their geographical footprint, especially in fast‑growing Asian markets where the United States and China together are projected to account for over 55 % of total sales by 2027. These companies are also investing heavily in R&D to develop next‑generation stationary phases that improve retention of highly polar metabolites.
Meanwhile, emerging players such as Restek, Welch Materials and Tosoh Bioscience are leveraging strategic partnerships with academic laboratories to accelerate product validation. Their focus on niche applications—like metabolomics and glycan profiling—helps diversify the overall market and provides customers with specialized solutions that larger firms may not prioritize.
Thermo Fisher Scientific Inc.
Bio‑Rad Laboratories, Inc.
Fortis Life Sciences, LLC.
BioCat GmbH
Takara Bio Inc.
Danaher Corporation
The global HILIC Columns market was valued at US$140 million in 2025 and is projected to reach US$189 million by 2032, expanding at a CAGR of 4.4% over the forecast horizon. This steady growth is driven by the increasing adoption of Hydrophilic Interaction Liquid Chromatography in pharmaceutical R&D, where the technique’s ability to resolve highly polar analytes underpins the development of novel drug substances and metabolites. In parallel, the U.S. market size is estimated at $ million in 2025 while China is poised to reach $ million, reflecting the expanding biotech ecosystems in both regions. The silica‑based segment—the most mature technology—will reach $ million by 2032, benefiting from continuous improvements in particle uniformity and surface chemistry that enhance reproducibility and column longevity. Together, these dynamics underscore a market maturing through incremental innovation rather than disruptive breakthroughs.
Personalized Medicine
Personalized medicine is intensifying demand for high‑resolution separation of biomarkers, metabolites, and small‑molecule therapeutics. As clinicians increasingly rely on metabolomic and proteomic signatures to tailor treatment regimens, the need for reliable polar‑compound analysis drives HILIC column adoption across clinical laboratories. The expanding use of liquid‑chromatography‑mass‑spectrometry (LC‑MS) platforms—particularly in oncology and rare‑disease diagnostics—creates a feedback loop that accelerates column development, with manufacturers focusing on low‑dead‑volume designs and enhanced pH stability to meet stringent regulatory standards. Consequently, the market is witnessing a shift toward application‑specific columns that align with the precision required for patient‑centric therapeutic strategies.
The broader expansion of biotechnological research fuels sustained demand for HILIC columns. Universities, contract research organizations, and large‑scale biopharma firms are scaling up workflows that involve glycan profiling, nucleotide analysis, and environmental monitoring of polar contaminants. Advances in polymer‑based and zwitterionic stationary phases broaden the analytical toolbox, offering superior selectivity for challenging matrices. Moreover, collaborations between column manufacturers and instrument vendors are accelerating the rollout of integrated solutions that combine optimized mobile phases with automated data‑processing algorithms, reducing method‑development time. While the market benefits from these synergies, manufacturers also confront challenges such as raw‑material price volatility for high‑purity silica and the need to maintain stringent quality controls across a fragmented supply chain. Nevertheless, the cumulative effect of research investment and cross‑industry partnerships positions the HILIC Columns market for continued, measured expansion.
North America remains the dominant region for HILIC Columns, accounting for roughly a quarter of the global market in 2025. The United States leads the segment, driven by a high concentration of pharmaceutical R&D facilities, extensive biopharmaceutical manufacturing, and well‑established academic research institutions. The region benefits from strong funding for life‑science research, frequent adoption of advanced analytical techniques, and a mature regulatory environment that encourages the use of high‑performance liquid chromatography (HPLC) methods such as HILIC. In addition, the presence of major column manufacturers—Thermo Fisher Scientific, Agilent, and Waters—ensures rapid introduction of innovative stationary phases, reinforcing the market’s growth. While Canada and Mexico contribute modestly, they are experiencing steady expansion as biotech clusters emerge in Toronto and Montreal, and as Mexican pharmaceutical firms modernize their analytical labs.
Key Highlights:
Europe represents the second‑largest market for HILIC Columns, with Germany, the United Kingdom, and France driving the majority of demand. The region’s strong pharmaceutical manufacturing base, combined with a mature analytical services sector, creates a steady requirement for high‑efficiency HILIC separations, especially in the analysis of biologics and small‑molecule drugs. The European Union’s Horizon Europe program has allocated billions of euros to life‑science research, fostering the adoption of cutting‑edge chromatography technologies. Moreover, strict environmental regulations encourage the use of greener solvents, positioning HILIC— which reduces water usage— as a preferred technique. The market is also supported by the presence of key players such as Merck and Tosoh Bioscience, which have local production facilities and close collaborations with academic institutes. While the market growth is moderate compared with North America, the emphasis on sustainability and precision medicine is expected to keep European demand robust through 2032.
Key Highlights:
Asia‑Pacific is projected to be the fastest‑growing region for HILIC Columns between 2026 and 2034, with a compound annual growth rate that exceeds the global average. China’s rapid expansion of biopharmaceutical manufacturing, coupled with substantial government incentives for life‑science research, makes it the largest contributor within the region. Japan and South Korea also display strong demand, driven by their advanced pharmaceutical pipelines and extensive use of metabolomics in drug discovery. The widespread adoption of HILIC in metabolomics and glycomics is especially pronounced in academic institutions across India and Southeast Asia, where cost‑effective high‑throughput analysis is essential. Additionally, the shift toward continuous manufacturing and quality‑by‑design (QbD) practices in the region necessitates reliable polar separations, further fueling column sales. Although the market is still less mature than North America or Europe, the sheer scale of investment—particularly the Chinese government’s “Made in China 2025” plan—ensures sustained growth.
Key Highlights:
South America’s HILIC Columns market is smaller but steadily expanding, led primarily by Brazil and Argentina. The growth is closely linked to the region’s increasing pharmaceutical production capacity and a rising trend of outsourcing analytical services to contract research organizations (CROs). Brazilian biotech clusters in São Paulo and Rio de Janeiro have begun integrating HILIC methods to address complex polar analytes in natural product research, a field traditionally strong in the region. Argentine laboratories are adopting HILIC for food‑safety testing, reflecting a broader move toward high‑performance separations in agricultural industries. While investment levels are lower than in North America or APAC, government programs supporting scientific innovation—such as Brazil’s “Science, Technology and Innovation” agenda—are creating a more favorable environment for advanced chromatography. The market’s moderate growth is expected to continue as local manufacturers such as YMC expand distribution networks, improving accessibility and technical support.
Key Highlights:
The Middle East & Africa (ME&A) region presents a niche yet promising market for HILIC Columns. In the Gulf Cooperation Council (GCC) states—particularly the United Arab Emirates and Saudi Arabia—significant investment in pharmaceutical manufacturing and clinical research is reshaping the analytical landscape. High‑value projects such as the Dubai Science Park and Saudi Arabia’s Vision 2030 have attracted multinational CROs, which are incorporating HILIC to meet stringent regulatory requirements for polar compound analysis. In contrast, sub‑Saharan Africa remains focused on basic laboratory capacity building, with limited but growing adoption of advanced chromatography in university research programs. The presence of regional distributors for major manufacturers, combined with increasing training initiatives, is gradually lowering the barrier to entry. While the overall market share is modest, the projected CAGR aligns with the global 4.4% growth, supported by ongoing healthcare infrastructure development and a rising demand for sophisticated bio‑analytical methods.
Key Highlights:
North America currently accounts for the largest share of the global HILIC Columns market, supported by a high concentration of pharmaceutical R&D centers, robust biomanufacturing activity, and the presence of leading column manufacturers that drive continual product innovation.
Key Highlights:
Asia‑Pacific is projected to witness the fastest growth during the forecast period, driven by rapid biopharmaceutical expansion, substantial government funding for life‑science research, and increasing adoption of metabolomics and glycomics in academic and industrial settings.
Key Highlights:
How is the expansion of biopharmaceutical research influencing regional demand for HILIC Columns?
The ongoing expansion of biopharmaceutical research is significantly increasing demand for HILIC Columns globally, as developers require reliable separation of highly polar intermediates, metabolites, and biologics. Regions with intensive biomanufacturing activities see higher adoption rates because HILIC provides superior resolution for compounds that are challenging for traditional reversed‑phase methods.
Key Highlights:
Countries such as the United States, China, Germany, Japan, and the United Arab Emirates are emerging as major investment hubs for HILIC Columns. Strong R&D funding, expanding biopharma production, and strategic initiatives to modernize analytical laboratories are creating substantial growth opportunities.
Smart manufacturing initiatives and the rise of advanced analytical platforms are playing a critical role in accelerating regional demand for HILIC Columns. Integration of automated sample preparation, high‑throughput screening, and real‑time data analytics requires reliable, reproducible chromatography, positioning HILIC as a preferred choice for polar analyte separation.
Key Highlights:
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.
✅ Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
✅ Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
✅ Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
✅ Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
✅ Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
✅ Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
✅ Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
✅ Stakeholder Insights
Target audience includes manufacturers, suppliers, distributors, investors, regulators, and policymakers
-> Key players include Thermo Fisher Scientific, Agilent Technologies, Merck KGaA, Restek Corporation, Phenomenex, Shimadzu Corporation, Waters Corporation, Welch Materials, Tosoh Bioscience, YMC, HILICON, Hawach Scientific, Cytiva, Advanced Materials Technology, and FarCitech.
-> Key growth drivers include increasing demand for polar and hydrophilic compound analysis in pharmaceutical and biotech research, expansion of metabolomics and glycomics studies, rising adoption of ultra‑high‑performance liquid chromatography (UHPLC) platforms, and growing regulatory requirements for food safety testing.
-> Asia-Pacific is the fastest‑growing region, driven by strong pharmaceutical manufacturing in China, Japan, and South Korea, while Europe remains the largest market in terms of revenue due to mature biotech sectors in Germany, France, and the United Kingdom.
-> Emerging trends include development of sustainable stationary phases (e.g., bio‑based silica and polymer supports), integration of HILIC columns with microfluidic and AI‑enhanced data analytics platforms, and the launch of mixed‑mode columns that combine HILIC with reversed‑phase characteristics for broader applicability.
